

**CMBI Credit Commentary****Fixed Income Daily Market Update 固定收益部市场日报****The Asset Asian G3 Bond Benchmark Review 2023**

We hope you found our commentaries and ideas helpful. We seek to elevate our efforts and value-add further in the coming year. We highly appreciate your support to us in Sell-Side Analysts of the polls of "[The Asset Asian G3 Bond Benchmark Review 2024](#)". Thank you for your support!

- *New NWDEVL'28 down 2pts this morning. Asian IG widened 10-20bps with better selling flows while we saw buying interests on belly CKHH and TENCNT. GRWALL/HRINTH were also well bid. LGFV space was stable.*
- *EHICAR: Delay in closing the onshore syndicated loans should be temporary; maintain buy. EHICARs were unchanged to 1pt lower this morning. See comments below.*
- *MEDCIJ: Improved credit profile in 1H24. Maintain buy on MEDCIJ'28/29. MEDCIJs were down 0.3 to 1.3pts this morning. See comments below.*

**❖ Trading desk comments 交易台市场观点**

Last Friday, UST yields tightened 12-20bps overnight and Asia IG space was under better selling. The new NWDEVL '28 closed 1.2pts lower from par. NWDEVL Perps/27-31s declined 0.8-1.7pts under profit taking from PBs/RMs. That said, these bonds/perps still closed 2.6-4.4pts higher WoW. In KR, the recently issued DAESEC 5.5 '27 widened 6bps. LGENSO/LGELEC/HYNMTR 29s closed 7-10bps wider. In Chinese IGs, HAOHUA/SINOCH 28-31s widened 3-7bps. TENCNT/BABA 27-31s were 2-8bps wider. In Chinese AMCs, GRWALL 7.15 Perp was 0.1pt higher. CCAMCL/ORIEAS 27-30s were 6-12bps wider. CSFCO/CISIFG/GTJA Float 27s tightened 1-2bps. In regional financials, NANYAN/BNKEA T2s widened 7-13bps under heavy profit taking. BBLTB/OCBCSP 34s widened 4-7bps. ANZ/WSTP 30s, on the other hand, tightened 2-4bps. In AT1s, ICBCAS/BOCOM Perps were 0.1-0.2pt higher. In EU AT1s, the recent issues such as SANTAN 8 Perp/DNBNO 7.375 Perp were down 0.4pt. ACAFP 6.5 Perp/SOCGEN 8.5 Perp/INTNED 8 Perp were 0.2-0.7pt lower. Chinese properties were mixed. CHIOLIs were 0.8-2.1pts higher. On the other hand, VNKRL 27/29 were 0.4-0.6pt lower. ROADKGs were down 0.3-0.6pt. In industrials, EHICAR '27/WESCHI '26 were up 0.3-0.4pt. In Macau gaming, SANLTD 27-30s were 0.4-0.7pt higher. MEPL/WYNMAC 27-29s were 0.3-0.6pt lower. In India, UPLLIN 28/30/Perp were 1.8-2.3pts lower following its 1Q25 results with lower margin and higher net debts. Azure Power announced early results of its tender offer and accepted for purchase USD8mn of AZUPOE 3.575 '26. AZUPOEs closed unchanged.

In LGFVs, CPDEV 25/26 and ZHHFGR '25 were 0.2-0.3pt higher. On the other hand, HNYUZI/GSHIAV 27s were down 0.1-0.2pt. SDECDI '26 was

PLEASE READ THE AUTHOR CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE

**Glenn Ko, CFA 高志和**  
(852) 3657 6235  
glennko@cmbi.com.hk

**Cyrena Ng, CPA 吳蒨瑩**  
(852) 3900 0801  
cyrenang@cmbi.com.hk

**Jerry Wang 王世超**  
(852) 3761 8919  
jerrywang@cmbi.com.hk

0.3pt lower. In SOE perps, CHPWCN 4.25 Perp/CHSCOI 3.4 Perp were 0.1pt higher. CHCOMU 3.65 Perp was 0.1pt lower. In the high beta names, HUANEN '31/HNINTL '29 were 0.9-1.1pts higher. SUNSHG '26 was down 0.2pt. TIANFS '26 was 0.1pt lower.

#### ❖ Last Trading Day's Top Movers

Top Performers	Price	Change	Top Underperformers	Price	Change
SINOPE 3.68 08/08/49	84.5	2.7	UPLLIN 4 5/8 06/16/30	82.8	-2.3
TAISEM 4 1/2 04/22/52	99.2	2.6	UPLLIN 5 1/4 PERP	72.9	-2.2
SINOPE 4 1/4 04/12/47	93.1	2.6	UPLLIN 4 1/2 03/08/28	88.0	-1.8
SINOPE 4 09/13/47	89.5	2.5	NWDEVL 4 1/8 PERP	68.0	-1.7
TAISEM 3 1/4 10/25/51	79.5	2.5	NWDEVL 6 1/4 PERP	57.4	-1.7

#### ❖ Marco News Recap 宏观新闻回顾

**Macro** – S&P (-1.84%), Dow (-1.51%) and Nasdaq (-2.43%) remained weak on Last Friday. US Jul'24 NFP was +114k, lower than the expectation of +176k. US Jul'24 unemployment rate was 4.3%, higher than the expectation of 4.1%. China Caixin Jul'24 service PMI was 52.1, higher than the expectation of 51.4. UST yields retreated on Friday, 2/5/10/30 yield reached 3.88%/3.62%/3.80%/4.11%.

#### ❖ Desk analyst comments 分析员市场观点

##### ➤ EHICAR: Delay in closing the onshore syndicated loans should be temporary; maintain buy

EHICAR'26/27 were 8.5-9pts lower since early Jul'24, partly due to the concerns of delay in closing the onshore syndicated loans. We believe that the delay is temporary and continue to expect EHICAR's credit profile to improve considerably over the next 2-3 years given the gradual recovery of its operating performance and the increasing uses of operating lease model starting from 2Q23. We maintain buy on EHICARs and believe that the lower cash prices offer better entry points. The conclusion and upsize, if any, of the onshore syndicated loans could be a catalyst for outperformance in the near-term.

During the investors' call in Jun'24, EHICAR mentioned that it would close the syndicated loans of RMB800mn-1bn in early Jul'24. As per our recent discussions with EHICAR, the delay in closing the syndicated loans was mainly attributable to more participating banks in the syndicated loans than originally expected. The credit approval process is therefore lengthened but terms (3-yr and funding cost below 5%) of the syndicated loans are the largely the same as previously communicated to the market. We would monitor if the final loan size will be larger than RMB800mn-1bn as per previously indicated.

On a separate note, after the active fleet size expansion in 1Q24, EHICAR has more or less completed its fleet expansion in the near-term and has turned its focus to ramp up the fleet utilization. The company noted the improvement in operating stats such as fleet utilization rate and ADRR from Jun'24. 3Q is traditionally a peak of the car rental industry. The improvement should be more obvious. More detailed operating stats and guidance will be available when EHICAR will release its 1H24 results in Sep'24.

Regarding the IPO in the US, EHICAR has obtained CAC approval, and is pending on the approval from CSRC. EHICAR does not have a concrete IPO timetable.

Security Name	ISIN	Amt Out (USD mn)	Ask Price	YTM (Ask)	Rating(M/S/F)
EHICAR 7 ¾ 11/14/24	XS2335327388	44.6	100.5	5.7	-/-/-

EHICAR 7 09/21/26	XS2384059122	300.0	78.1	20.2	-/-
EHICAR 12 09/26/27	XS2782510049	325.0	83.3	19.3	-/-

Source: Bloomberg.

### ➤ MEDCIJ: Improved credit profile in 1H24. Maintain buy on MEDCIJ'28/29

Medco Energi (Medco) released largely stable 1H24 results. In 1H24, Medco's oil and gas production was 153 mboepd, higher than the company's guidance of 145-150 mboepd but 5.6% lower than that in 1H23. The impact of lower oil and gas production was offset by higher ASP. Hence, Medco's revenue in 1H24 rose 4.4% yoy to USD1,165mn and its EBITDA increased 2% yoy to USD650mn. We expect Medco's revenue and EBITDA to reach cUSD2.35bn and cUSD1.3bn in FY24, slightly higher than USD2.25bn and USD1.26bn in FY23, respectively.

Medco's credit profile remained solid for its credit ratings. As of Jun'24, Medco had cash on hand of USD663.5mn, increased 52.3% from USD435.7mn in Dec'24. Its total debts decreased 2.3% to USD3.45bn from USD3.53bn in Dec'24. Its net debt to EBITDA ratio improved to 1.7x from 2.1x in Dec'23. We consider Medco's cash on hand and operating cash inflow to be sufficient to cover its ST debts of USD378mn and capex of cUSD240mn in 2H24.

Medco has actively managed its maturities in the past year. It early redeemed due 25-28 MEDCIJs totaled USD545mn via tender offers since Nov'23 and early called USD33mn MEDCIJ'25 in May'24. We expect Medco to conduct more early redemptions or early calls given its sufficient liquidity and good access to onshore funds. In 1H24, Medco issued IDR bonds of USD95mn with coupon rates ranging from 7.35 to 8.5%. In 2Q24, both S&P and Fitch upgraded Medco one notch to BB- with stable outlook on enhanced financial flexibility. MEDCIJs rose 1.3-4pts in 2024, we maintain buy on MEDCIJs and prefer MEDCIJ 28/29 for better risk-return profile within the curve.

Security Name	ISIN	Amt Out (USD mn)	Ask Price	YTM (Ask)	Rating(M/S/F)
MEDCIJ 7 % 05/14/26	US58405FAA30	314.7	101.4	6.5	B1/BB-/BB-
MEDCIJ 6 % 01/30/27	US58406LAA98	498.7	99.5	6.6	B1/BB-/BB-
MEDCIJ 6.95 11/12/28	US58406RAA68	299.4	100.2	6.9	B1/BB-/BB-
MEDCIJ 8.96 04/27/29	US58407HAA77	500.0	106.1	7.4	B1/BB-/BB-

Source: Bloomberg.

### ➤ Offshore Asia New Issues (Priced)

Issuer/Guarantor	Size (USD mn)	Tenor	Coupon	Priced	Issue Rating (M/S/F)
No Offshore Asia New Issues Priced Today					

### ➤ Offshore Asia New Issues (Pipeline)

Issuer/Guarantor	Currency	Size (USD mn)	Tenor	Pricing	Issue Rating (M/S/F)
Henan Investment Group Co., Ltd.	USD	-	3yr	-	-/-/A

### ➤ News and market color

- Regarding onshore primary issuances, there were 60 credit bonds issued last Friday with an amount of RMB43bn. As for Month-to-date, 130 credit bonds were issued with a total amount of RMB141bn raised, representing a 42.5% yoy increase
- [ADTIN]** Adani Energy Solutions raises USD1bn in shares via QIP

- **[AZUPOE]** Azure Power announced early results of tender offer for USD8mn of AZUPOE 3.575'26
- **[DALWAN]** Media reported that Dalian Wanda Commercial Management Group's RMB150mn equity interests in Qingdao Licang Wanda Plaza and and Xi'an Daming Palace Wanda Plaza frozen by court
- **[GEMDAL]** Media reported that Gemdale US unit sold Seattle luxury high-rise for USD175mn
- **[NWDEVL]** New World Development will convene a EGM on 22 Aug'24 to vote on USD200mn disposal
- **[VEDLN]** Vedanta unit Hindustan Zinc's 1Q25 revenue rose 12% yoy to cUSD971mn and EBITDA rose 17% yoy to cUSD471mn
- **[YIDCHL]** Yida China received additional share trading resumption guidance from HKEx

*Fixed Income Department*

*Tel: 852 3657 6235/ 852 3900 0801*

[fis@cmbi.com.hk](mailto:fis@cmbi.com.hk)

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

## Author Certification

The author who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the author covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that author in this report.

Besides, the author confirms that neither the author nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

## Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM and/or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

### Disclaimer:

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.,") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US Securities Exchange Act of 1934, as amended, and may not be furnished to

any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.